fashion -WSS

fashion

author：leisure time 2025-09-30 00:02:54 - browse：9

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： White House drug shortage group privately met with industry

WSS

Europe sees delivery challenges ahead on Alzheimer's therapies

What the cancer research community can learn from the Covid response

Humana, CVS hope to turn members into patients at clinics

What the cancer research community can learn from the Covid response

Federal judge rules Oregon’s tough new gun law is constitutional

Europe sees delivery challenges ahead on Alzheimer's therapies

focus

fashion

explore

Hepatitis C has a cure — but many Americans still lack access to it

White House drug shortage group privately met with industry

Medicare proposal to cover medical devices draws a mixed reaction

Mike Pence clashes with Tucker Carlson in Iowa

Guidelines to prevent youth baseball injuries need more muscle

Blood tests recalled over risk of missed heart attack diagnosis

ChatGPT in medicine: STAT answers readers' burning questions

Mike Pence clashes with Tucker Carlson in Iowa

How one medical school became remarkably diverse

A cyberattack has disrupted hospitals and health care in several states

focus

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

TytoCare raises $49 million to build out AI

Mike Pence clashes with Tucker Carlson in Iowa

Dramatically reducing cancer deaths requires the PASTEUR Act

ER docs worry over extreme heat as a 'mass casualty event'

Stem cell clinics for heart failure: buyer be wary

explore

focus

hotspot

focus